Abiopharma

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

Zymeworks Announces Participation in Upcoming Investor Conferences

Rockwell Medical to Exhibit at ASN Kidney Week 2025

LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Change of Directors Interest Notice

Notification regarding unquoted securities - MSB

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA